What Escient Pharmaceuticals does

Escient Pharmaceuticals was a clinical-stage biotechnology company founded in 2017 and headquartered in San Diego, California, focused on developing first-in-class oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory axis. The company built its pipeline around the unmet needs of patients with mast cell-mediated disorders and severe pruritus conditions, including chronic inducible urticaria, chronic spontaneous urticaria, atopic dermatitis, and cholestatic/uremic pruritus associated with primary biliary cholangitis, primary sclerosing cholangitis, and chronic kidney disease. The company served these patient populations through clinical-stage drug development rather than commercial sales.

The core technology centered on an industry-leading MRGPR platform combining proprietary genetic models, GPCR-focused pharmacology, and medicinal chemistry capabilities. The lead clinical programs were EP262, a once-daily oral MRGPRX2 antagonist for mast cell-mediated diseases that blocks IgE-independent mast cell activation, and EP547, an oral MRGPRX4 antagonist that blocks bile acid-, bilirubin-, and urobilin-driven pruritus signaling. Both candidates were wholly-owned, first-in-class, and supported by Phase 1 safety and pharmacokinetic data; additional discovery-stage programs targeted MRGPRD and MRGPRX1.

Escient operated as a pre-revenue, venture-backed biotech with no commercial products and no disclosed pricing. The business model relied on advancing candidates through clinical milestones to create exit value through M&A or partnership rather than independent commercialization. The company raised approximately $237.5 million across three disclosed financing rounds from top-tier life science investors including NEA, Abingworth, The Column Group, 5AM Ventures, and Sanofi Ventures. In May 2024, Incyte Corporation completed its acquisition of Escient for $750 million plus net cash, transferring EP262 and EP547 into Incyte's Inflammation and Autoimmunity portfolio.

Name

Escient Pharmaceuticals

Legal name

Escient Pharmaceuticals Inc

Website

https://escientpharma.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

11–50 employees

Short description

Escient Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) for mast cell-mediated disorders and pruritus conditions. Acquired by Incyte in May 2024 for $750 million plus net cash.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Mast Cell Disorders Specialty Care (HLAKAAAH)

Keywords

• Clinical-stage biotechnology
• Small molecule therapeutics
• GPCR drug discovery
• MRGPR antagonists
• Neurosensory-inflammatory disorders

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company. Revenue will be generated through commercialization of novel therapeutics following regulatory approval. The company was acquired by Incyte for $750 million in May 2024, indicating successful exit strategy through M&A rather than independent commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Escient Pharmaceuticals develops first-in-class, oral small molecule therapeutics that antagonize Mas-related G protein-coupled receptors (MRGPRs) for the treatment of mast cell-mediated and pruritic disorders. Its lead candidates, EP262 (MRGPRX2 antagonist) and EP547 (MRGPRX4 antagonist), are being advanced for chronic urticaria, atopic dermatitis, and cholestatic/uremic pruritus, supported by an in-house MRGPR-focused drug discovery platform.

Product overview

Escient Pharmaceuticals is a clinical-stage biotechnology company developing a pipeline of first-in-class, oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory axis. The company's lead product candidates include EP262 (MRGPRX2 antagonist) for mast cell-mediated disorders such as chronic urticaria and atopic dermatitis, and EP547 (MRGPRX4 antagonist) for cholestatic and uremic pruritus. All programs are wholly-owned and the company was acquired by Incyte in May 2024.

Differentiator

Problem solved

Functional benefit

Products and services

• EP262 (MRGPRX2 Antagonist) Potent, highly selective, once-daily oral small molecule antagonist of MRGPRX2 for the potential treatment of mast cell-mediated diseases including chronic inducible urticaria (CIndU), chronic spontaneous urticaria (CSU), and atopic dermatitis; designed to block IgE-independent mast cell activation.
• EP547 (MRGPRX4 Antagonist) Potent, highly selective antagonist that blocks MRGPRX4 activation by bile acids, bilirubin, and urobilin for the potential treatment of cholestatic and uremic pruritus, offering a disease-specific oral alternative to non-specific pruritus therapies.
• MRGPRD Program Early-stage discovery program targeting the MRGPRD receptor as part of Escient's broader MRGPR-focused neurosensory-inflammatory pipeline; specific indication undisclosed.
• MRGPRX1 Program Early-stage discovery program targeting the MRGPRX1 receptor as part of Escient's broader MRGPR-focused neurosensory-inflammatory pipeline; specific indication undisclosed.

Quantifiable outcome

• EP262 Phase 1 study (64 healthy volunteers): safe and well-tolerated at all doses with no serious adverse events, no adverse events leading to discontinuation, and no clinically meaningful changes in safety parameters
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Incyte CorporationcoreStrategic or Co-development PartnerIncyte acquired Escient Pharmaceuticals in May 2024 for $750 million plus net cash. The acquisition strengthens Incyte's Inflammation and Autoimmunity (IAI) pipeline with EP262 and EP547, first-in-class oral MRGPR antagonists.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Novartis: Developing remibrutinib, an oral TYK2 inhibitor in Phase 3 for chronic spontaneous urticaria — the same indication as Escient's EP262, making it the most direct oral competitor in IgE-independent CSU treatment.
• Cara Therapeutics: Clinical-stage biotech focused on pruritus therapeutics (KORSUVA/difelikefalin for uremic and cholestatic pruritus), directly competing with EP547 in the same disease settings and pursuing oral alternative formulations.
• Allakos Inc. Developed anti-Siglec-8 antibody lirentelimab for chronic spontaneous urticaria and other mast cell/eosinophil-driven diseases, overlapping with EP262's IgE-independent mast cell approach.
• Evommune Inc. Clinical-stage immunology and dermatology company developing oral small molecules (including MRGPRX2 antagonists such as EVO756) for chronic spontaneous urticaria, directly paralleling Escient's EP262 program.
• Arcutis Biotherapeutics: Dermatology-focused biotech commercializing topical roflumilast (ZORYVE) for atopic dermatitis and seborrheic dermatitis, sharing atopic dermatitis and pruritus indications with Escient's EP262/EP547.
• Dermavant Sciences: Dermatology-focused company developing topical tapinarof (VTAMA) for atopic dermatitis and other inflammatory skin diseases, overlapping commercially with EP262's atopic dermatitis indication.

Broad incumbents

• Regeneron Pharmaceuticals: Co-developer (with Sanofi) of DUPIXENT (dupilumab), the leading biologic for atopic dermatitis and now chronic spontaneous urticaria — the dominant large-molecule competitor to Escient's EP262 across both indications.
• Sanofi: Commercializes DUPIXENT (dupilumab) with Regeneron in atopic dermatitis and chronic spontaneous urticaria, and was an Escient investor via Sanofi Ventures — a key strategic incumbent in the same therapeutic indications.
• Incyte Corporation: Acquired Escient in May 2024 for $750M plus net cash and now owns EP262/EP547 as part of its Inflammation and Autoimmunity franchise, alongside broader commercial dermatology/allergy assets including ruxolitinib cream (OPZELURA).
• Galderma: Global dermatology-focused pharmaceutical company with a broad portfolio in atopic dermatitis (e.g., nemolizumab), inflammatory skin conditions, and pruritus — overlapping with EP262/EP547 indications at a broader commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/escientp
• LinkedInlinkedin.com/company/escientpharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Escient Pharmaceuticals